Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.19.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Mar. 31, 2019
Mar. 31, 2018
REVENUE, NET    
Products $ 543,970 $ 197,554
Services 163,092
Total revenues, net 707,062 197,554
COST OF REVENUE    
Products 498,993 155,549
Services 22,781
Total costs of revenue 521,774 155,549
GROSS MARGIN 185,288 42,005
EXPENSES    
Sales and marketing 698,185 356,948
General and administrative 2,092,775 953,484
Depreciation and Amortization 40,627 224,770
Impairment of asset 893,667
TOTAL OPERATING EXPENSES 2,831,587 2,428,869
OPERATING LOSS (2,646,299) (2,386,864)
Other Income (Expense)    
Change in fair value of equity investments 429,755
Dividend received from equity investment 186,397
Interest Expense (648,875)
Total other (expense), net (32,723)
NET LOSS (2,679,022) (2,386,864)
Less: Net loss (income) attributable to non controlling interest 49,695 10,763
NET LOSS ATTRIBUTABLE TO APPLIED BIOSCIENCES CORP. $ (2,629,327) $ (2,376,101)
LOSS PER COMMON SHARE $ (0.22) $ (0.16)
WEIGHTED AVERAGE SHARES OUTSTANDING    
Basic and diluted 11,914,525 15,071,417